Target intelligence / Profile preview

Alphavirus envelope glycoprotein (E1/E2)

Target
E1/E2
Molecular classification
Viral surface protein, Class II viral fusion protein, Glycoprotein
01

Overview

The Alphavirus envelope glycoproteins, primarily E1 and E2, are structural proteins that form icosahedral spikes on the surface of the virion. E2 is a type I transmembrane protein responsible for receptor binding and attachment to the host cell surface, while E1 is a class II fusion protein that mediates the fusion of the viral envelope with the host endosomal membrane upon acidification. These proteins are synthesized as a polyprotein precursor (p62-6K-E1) that is proteolytically processed during transport to the cell surface. Because they are the most exposed components of the virus, they serve as the primary targets for the host immune response and are the focus of vaccine and monoclonal antibody development. Therapeutic strategies often aim to block the E2-mediated attachment or the E1-mediated conformational change required for membrane fusion, thereby preventing viral entry and subsequent replication.

Other names
Alphavirus spike proteinE1 glycoproteinE2 glycoproteinE3 glycoproteinAlphavirus structural protein
02

Mechanism of action

Neutralization of viral particles by blocking receptor attachment (E2) or inhibiting pH-dependent membrane fusion (E1) within the endosome.

03

Biological functions

Viral entryReceptor bindingMembrane fusionViral assemblyViral budding
04

Disease associations

InfectionChikungunya feverVenezuelan equine encephalitisRoss River virus infectionMayaro virus diseaseSindbis virus infection
05

Safety considerations

Antigenic drift and viral escape mutationsPotential for antibody-dependent enhancement (ADE)Cross-reactivity with host proteinsHigh variability between different alphavirus species
06

Interacting drugs

VLA1553 (Ixchiq)

4 more in the full profile.

07

Biomarkers

Anti-E2 neutralizing antibody titerViral RNA loadE1-specific IgG/IgM

Beyond the preview

Go deeper on Alphavirus envelope glycoprotein (E1/E2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphavirus envelope glycoprotein (E1/E2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call